enow.com Web Search

Search results

  1. Results from the WOW.Com Content Network
  2. Atlas of cells transforms understanding of human body - AOL

    www.aol.com/atlas-cells-transforms-understanding...

    An ambitious plan to map all 37 trillion cells in the human body is transforming understanding of how our bodies work, scientists report. ... one of the founders who now works at now at Genentech ...

  3. Genentech - Wikipedia

    en.wikipedia.org/wiki/Genentech

    Genentech, Inc. is an American biotechnology corporation headquartered in South San Francisco, California, wholly owned by the Swiss multinational pharmaceutical company, the Roche Group. It became an independent subsidiary of Roche in 2009.

  4. Human Cell Atlas - Wikipedia

    en.wikipedia.org/wiki/Human_Cell_Atlas

    The Human Cell Atlas is a global consortium that is creating detailed maps of the cells in the human body to transform understanding of health and disease. Organisms: Human: Contact; Primary citation: Regev, Aviv; et al. (Human Cell Atlas Organizing Committee) (2018). "The Human Cell Atlas White Paper". arXiv: 1810.05192 . Access; Website

  5. Cortical homunculus - Wikipedia

    en.wikipedia.org/wiki/Cortical_homunculus

    A 2-D model of cortical sensory homunculus. A cortical homunculus (from Latin homunculus 'little man, miniature human' [1] [2]) is a distorted representation of the human body, based on a neurological "map" of the areas and portions of the human brain dedicated to processing motor functions, and/ or sensory functions, for different parts of the body.

  6. Genentech to Present Important New Data Reflecting Broad ...

    www.aol.com/news/2013-05-15-genentech-to-present...

    About Genentech Founded more than 30 years ago, Genentech is a leading biotechnology company that discovers, develops, manufactures and commercializes medicines to treat patients with serious or ...

  7. Bill Anderson (businessman) - Wikipedia

    en.wikipedia.org/wiki/Bill_Anderson_(businessman)

    From 2017 to 2018, he was the CEO of Genentech. [6] While at Genentech, he developed its immunology and ophthalmology divisions, managed the sales of Rituxan, Raptiva, and Xolair, and directed Roche's late-stage portfolio committee for nearly four years, where he was responsible for determining late-stage clinical trial advancements. [6]

  8. Genentech withdraws use of Gavreto in US for a type of ... - AOL

    www.aol.com/news/genentech-withdraws-gavreto-us...

    Genentech previously said the use of the drug in the indication accounts for a fraction of its overall revenue. The U.S. Food and Drug Administration had granted accelerated approval to Gavreto in ...

  9. Aviv Regev - Wikipedia

    en.wikipedia.org/wiki/Aviv_Regev

    Aviv Regev (born 11 July 1971) [3] is a computational biologist and systems biologist and Executive Vice President and Head of Genentech Research and Early Development in Genentech/Roche. [4] She is a core member (on leave) at the Broad Institute of MIT and Harvard and professor (on leave) at the Department of Biology of the Massachusetts ...